Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-11T10:32:20.313Z Has data issue: false hasContentIssue false
  • English
  • Français

Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives

Published online by Cambridge University Press:  01 January 2021

Chantal M. Morel  and
Suzanne E. Edwards
Get access Rights & Permissions [Opens in a new window]

Extract

The ability to sustain antibiotic efficacy is directly affected by incentive models aiming to stimulate antibiotic research and development. This paper analyzes the extent to which the models proposed by the Innovative Medicine Initiative-funded research project DRIVE-AB can be expected to support sustainable use, drawing on basic economic theory and the incentives that derive from it. It then discusses the use of minimal safeguards that will be needed to support sustainable use where industry incentives have not been re-aligned with those of public health.

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue S1: Incentives to Stimulate Research and Development of New Antibiotics: Detailed Assessments of Select Incentives and Models , Spring 2018 , pp. 75 - 80
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

DRIVE-AB, available at <http://drive-ab.eu/> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
DRIVE-AB Final Report, “Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access,” 2018, available at <http://www.imi.europa.eu/projects-results/project-factsheets/drive-ab> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
See DRIVE-AB Final Report, supra note 2, at 15.Google Scholar
Essential Medicines and Health Products Information Portal, “Promoting Rational Use of Medicines: Core Components-WHO Policy Perspectives on Medicines,” No. 005, September 2002, available at <http://apps.who.int/medicinedocs/en/d/Jh3011e/> (last visited March 31, 2018); WHO, WHO Global Strategy for Containment of Antimicrobial Resistance, 2001, available at <http://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf> (last visited March 31, 2018).+(last+visited+March+31,+2018);+WHO,+WHO+Global+Strategy+for+Containment+of+Antimicrobial+Resistance,+2001,+available+at++(last+visited+March+31,+2018).>Google Scholar
Outterson, K., Gopinathan, U., Clift, C., So, A., Morel, C., and Røttingen, J. A., “Delinking Investment in Antibiotic R&D from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality,” PloS Medicine 13, no. 6 (2016): e1002043; C. Clift, U. Gopinathan, C. Morel, K. Outterson, J. A. Røttingen, and A. So, ‘Towards a New Global Business Model for Antibiotics: Delinking Revenues from Sales,” 2015, Chatham House, available at <https://www.chathamhouse.org/sites/files/chathamhouse/field/field_document/20151009NewBusinessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf> (last visited March 31, 2018); J. O'Neill, Securing New Drugs for Future Generations: The Pipeline of Antibiotics — The Review on Antimicrobial Resistance (2015), available at <https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf> (last visited March 31, 2018); J. Rex, and K. Outterson, “Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach,” The Lancet Infectious Diseases 16, no. 4 (2016): 500–505.Google Scholar
Norris, P., Herxheimer, A., Lexchin, J., and Mansfield, P., “Drug Promotion: What We Know, What We Have Yet to Learn: Reviews of Materials in the WHO/HAI Database on Drug Promotion,” WHO, 2005, available at <http://apps.who.int/iris/bitstream/10665/69177/1/WHO_EDM_PAR_2004.3_eng.pdf> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewn, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., Möller, H., Moucheraud, C., Pécoul, B., Rägo, L., Rashidian, A., Ross-Degnan, D., Stephens, P. N., Teerawattananon, Y., ‘t Hoen, E. F., Wagner, A. K., Yadav, P., and Reich, M. R., “Essential Medicines for Universal Health Coverage,” The Lancet 389, no. 10067 (2017): 403–476.CrossRefGoogle Scholar
See DRIVE-AB Final Report, supra note 2.Google Scholar
Pulcini, C., Morel, C. M, Tacconelli, E., Beovic, B., de With, K., Goossens, H., Harbarth, S., Holmes, A., Howard, P., Morris, A. M., Nathwani, D., Sharland, M., Schouten, J., Thursky, K., Laxminarayan, R., and Mendelson, M., “Human Resources Estimates and Funding for Antibiotic Stewardship Teams Are Urgently Needed,” Clinical Microbiology and Infection 23, no. 11 (2017): 785–787.Google Scholar
Global Drug Facility of the Stop TB partnership, available at <http://www.stoptb.org/gdf/> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
Savic, M. and Årdal, C., “A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 9–24.Google Scholar
Baraldi, E., Lindahl, O., Savic, M., Findlay, D., and Årdal, C., “Antibiotic Pipeline Coordinators,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 25–31.CrossRefGoogle Scholar
European Commission Global Health Policy Forum, access case study from DNDi, 2016, available at <https://ec.europa.eu/research/health/pdf/hpforum/3_ghpforum_brussels_2016-12_dndi_casestudies.pdf> (last visited March 31, 2018).+(last+visited+March+31,+2018).>Google Scholar
Sagal, M. W., Slowinski, G., Freese, K., and Ferguson, S., “Intellectual Property and Other Contractual Issues in Cooperative Research and Development Agreements (CRADAs): Part I,” Licensing Executives Society Nouvelles 44, no. 1 (2009): 41–48.Google Scholar
See DRIVE-AB Final Report, supra note 2, at 55-57.Google Scholar